UBS Group
PDLI

UBS Group’s PDL BioPharma, Inc. PDLI Stock Holding History

UBS Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-84,455
Closed -$266K – 9203
2020
Q3 		$266K Buy
84,455
+2,760
+3% +$8.82K ﹤0.01% 4622
2020
Q2 		$238K Sell
81,695
-52,250
-39% -$165K ﹤0.01% 4676
2020
Q1 		$378K Sell
133,945
-23,210
-15% -$74.8K ﹤0.01% 4209
2019
Q4 		$510K Sell
157,155
-1,186,838
-88% -$3.45M ﹤0.01% 4822
2019
Q3 		$2.9M Buy
1,343,993
+394,537
+42% +$1.05M ﹤0.01% 2925
2019
Q2 		$2.98M Buy
949,456
+117,036
+14% +$380K ﹤0.01% 2789
2019
Q1 		$3.1M Sell
832,420
-420,346
-34% -$1.42M ﹤0.01% 2601
2018
Q4 		$3.63M Buy
1,252,766
+324,428
+35% +$891K ﹤0.01% 2463
2018
Q3 		$2.44M Buy
928,338
+171,437
+23% +$421K ﹤0.01% 3039
2018
Q2 		$1.77M Sell
756,901
-172,758
-19% -$482K ﹤0.01% 3274
2018
Q1 		$2.73M Buy
929,659
+186,343
+25% +$509K ﹤0.01% 2859
2017
Q4 		$2.04M Sell
743,316
-89,480
-11% -$275K ﹤0.01% 3181
2017
Q3 		$2.82M Buy
832,796
+110,683
+15% +$308K ﹤0.01% 2779
2017
Q2 		$1.78M Sell
722,113
-47,118
-6% -$108K ﹤0.01% 3128
2017
Q1 		$1.75M Buy
769,231
+723,977
+1,600% +$1.6M ﹤0.01% 3056
2016
Q4 		$96K Sell
45,254
-4,656
-9% -$13K ﹤0.01% 5328
2016
Q3 		$167K Buy
49,910
+5,081
+11% +$16.1K ﹤0.01% 4672
2016
Q2 		$140K Sell
44,829
-40,387
-47% -$135K ﹤0.01% 4798
2016
Q1 		$284K Buy
85,216
+34,639
+68% +$108K ﹤0.01% 4228
2015
Q4 		$180K Buy
50,577
+9,621
+23% +$40.3K ﹤0.01% 4759
2015
Q3 		$206K Sell
40,956
-48,940
-54% -$280K ﹤0.01% 4618
2015
Q2 		$577K Buy
89,896
+14,746
+20% +$98.8K ﹤0.01% 3992
2015
Q1 		$529K Sell
75,150
-23,968
-24% -$174K ﹤0.01% 4098
2014
Q4 		$764K Buy
+99,118
New +$784K ﹤0.01% 3797

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HW
Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

UBS Group's PDLI Position: Q4 2020 in Review

UBS Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 84,455 shares — an estimated $266K sold.

UBS Group first reported a position in PDLI in Q4 2014 and held it in 24 quarters. The position peaked at $3.63M in Q4 2018. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • UBS Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • UBS Group sold 84,455 PDL BioPharma, Inc. shares in Q4 2020, an estimated $266K.
  • UBS Group first reported a position in PDL BioPharma, Inc. in Q4 2014 and held it in 24 quarters.
  • UBS Group's PDL BioPharma, Inc. position peaked at $3.63M in Q4 2018.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.